WBA sends a message: Adapt or risk obsolescence
By Darpan Seth, chief executive officer of Nextuple, an omnichannel order management advisory and software firm
Opinion
AI can elevate independents’ inventory management
Das Pattathil, chief executive officer of OnePint.ai
Some alternatives to TV ads for pharmaceuticals
By Bradley Keefer, chief revenue officer at Keen Decision Systems
Technology can enhance shopping and customize care
By Deborah Weinswig, founder and chief executive officer of Coresight Research
Digital out-of-home ads are a smart bet for pharma
By David Weinfeld, cofounder and chief executive officer of Screenverse
AI: Invaluable tool or unintended hindrance to care?
By Grace Mahas and Jonathon Brown, director of content and chief growth officer, respectively, at Trend Hunter
Whitman has been the heart and soul of NACDS
David Pinto writes that his longtime friend Jim Whitman can never be replaced once he retires from NACDS. "It’s not just what he did, how often he did it, or how effectively he did it. Rather, it has been the unfailing presence of the man himself."
The new world of economic uncertainty
President Trump’s fluctuating tariff policies have complicated the decision-making process for executives.
New investment model can spark industry innovation
By Tom Furphy, chief executive officer and managing director of Consumer Equity Partners
Six imperatives for deploying artificial intelligence
By Jill Standish, senior managing director and global head of Accenture’s Retail industry group
Pharmacy chains can install retail media networks: Here’s how
By Angus Dowie, global head of sales at ADvendio
Industry legend Jim Devine is irreplaceable
David Pinto writes that Jim Devine spent a lifetime in chain drug retailing, and anyone or anything he touched was better for the experience.
The implications of Sycamore Partners’ blockbuster acquisition of WBA
The acquisition aims to reinforce Walgreens, Boots and other consumer brands by leveraging WBA’s health care expertise and Sycamore’s strength in retail.
Some conspicuous absences from Fortune’s list
David Pinto writes that surprising to some and not so surprising to others was the absence of any drug chain from the list.